CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro
- PMID: 20497692
CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro
Abstract
Background: Rapamycin (RAPA) is a relatively new immunosuppressant drug that functions as a serine/threonine kinase inhibitor to prevent rejection in organ transplantation. RAPA blocks activation of T-effector (Teff) cells by inhibiting the response to interleukin-2. Recently, RAPA was also shown to selectively expand the T-regulator (Treg) cell population. To date, no studies have examined the mechanism by which RAPA converts Teff cells to Treg cells.
Methods: Peripheral CD4(+)CD25(-) naive T cells were cultivated with RAPA and B cells as antigen-presenting cells (APCs) in vitro. CD4(+)CD25(-) T cells were harvested after 6 days and analyzed for expression of forkhead box protein 3 (Foxp3) using flow cytometry. CD4(+)CD25(+)CD127(-) subsets as the converted Tregs were isolated from the mixed lymphocyte reactions (MLR) with CD127 negative selection, followed by CD4 and CD25 positive selection using microbeads and magnetic separation column (MSC). Moreover, mRNA was extracted from converted Tregs and C57BL/6 naive CD4(+)CD25(+) T cells and Foxp3 levels were examined by quantitative real-time polymerase chain reaction (rt-PCR). A total of 1 x 10(5) carboxyfluorescein succinimidyl ester (CFSE)-labeled naive CD4(+)CD25(-) T cells/well from C57BL/6 mice were cocultured with DBA/2 or C3H maturation of dendritic cells (mDCs) (0.25 x 10(5)/well) in 96-well round-bottom plates for 6 days. Then 1 x 10(5) or 0.25 x 10(5) converted Treg cells were added to every well as regulatory cells. Cells were harvested after 6 days of culture and analyzed for proliferation of CFSE-labeled naive CD4(+)CD25(-) T cells using flow cytometry. Data were analyzed using CellQuest software.
Results: We found that RAPA can convert peripheral CD4(+)CD25(-) naive T Cells to CD4(+)Foxp3(+) Treg cells using B cells as APCs, and this subtype of Treg can potently suppress Teff proliferation and maintain antigenic specificity.
Conclusion: Our findings provide evidence that RAPA induces Treg cell conversion from Teff cells and uncovers an additional mechanism for tolerance induction by RAPA.
Similar articles
-
The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.Transpl Immunol. 2007 Apr;17(3):153-61. doi: 10.1016/j.trim.2007.01.002. Epub 2007 Jan 24. Transpl Immunol. 2007. PMID: 17331841
-
Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.Nephrol Dial Transplant. 2010 Mar;25(3):710-7. doi: 10.1093/ndt/gfp586. Epub 2009 Nov 9. Nephrol Dial Transplant. 2010. PMID: 19903662
-
Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin.Ann Hematol. 2011 Jun;90(6):617-24. doi: 10.1007/s00277-010-1121-z. Epub 2010 Nov 24. Ann Hematol. 2011. PMID: 21107839
-
FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents.Trends Pharmacol Sci. 2011 Mar;32(3):158-66. doi: 10.1016/j.tips.2010.12.004. Epub 2011 Jan 13. Trends Pharmacol Sci. 2011. PMID: 21237521 Review.
-
[CD4+CD25+Foxp3+ T lymphocytes: naturally occuring regulatory T cells].Pediatr Endocrinol Diabetes Metab. 2010;16(4):289-94. Pediatr Endocrinol Diabetes Metab. 2010. PMID: 21447271 Review. Polish.
Cited by
-
The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings.Front Cell Dev Biol. 2021 Aug 18;9:661532. doi: 10.3389/fcell.2021.661532. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34490235 Free PMC article. Review.
-
The role of basophils as innate immune regulatory cells in allergy and immunotherapy.Hum Vaccin Immunother. 2018 Apr 3;14(4):815-831. doi: 10.1080/21645515.2017.1417711. Epub 2018 Jan 18. Hum Vaccin Immunother. 2018. PMID: 29257936 Free PMC article. Review.
-
CD4+CD25+ regulatory T cell therapy in neurological autoimmune diseases.PeerJ. 2025 Jun 12;13:e19450. doi: 10.7717/peerj.19450. eCollection 2025. PeerJ. 2025. PMID: 40525111 Free PMC article. Review.
-
Percentage and function of CD4+CD25+ regulatory T cells in patients with hyperthyroidism.Mol Med Rep. 2018 Feb;17(2):2137-2144. doi: 10.3892/mmr.2017.8154. Epub 2017 Nov 27. Mol Med Rep. 2018. PMID: 29207121 Free PMC article.
-
Transiently reduced PI3K/Akt activity drives the development of regulatory function in antigen-stimulated Naïve T-cells.PLoS One. 2013 Jul 11;8(7):e68378. doi: 10.1371/journal.pone.0068378. Print 2013. PLoS One. 2013. PMID: 23874604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous